nach oben

Erschienen in:

04.10.2018 | NON-THEMATIC REVIEW

Perspectives on the role of brain cellular players in cancer-associated brain metastasis: translational approach to understand molecular mechanism of tumor progression

verfasst von: Masoom Raza, Peeyush Prasad, Pragya Gupta, Naveen Kumar, Taruna Sharma, Mandeep Rana, Aaron Goldman, Seema Sehrawat

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Brain metastasis is one of the leading causes of death among cancer patients. Cancer cells migrate to various sites and harbor different niche in the body which help cancer cells in their survival. The brain is one of the safest place where cancer cells are protected from immune cells. Breast, lung, and melanoma cancer cells have high propensity to migrate towards the brain. To enter the brain, cancer cells have to cross the blood brain barrier. Survival and finding new niche in the brain are directed by several mechanisms in which different cellular players take part such as astrocytes, microglia, Schwann cells, satellite cells, oligodendrocytes, and ependymal cells. Usually, cancer cells highjack the machinery of brain cellular players to survive in the brain environment. It has been shown that co-culture of M2 macrophage with cancer cells leads to increased proliferation and survival of cancer cells. One of the challenges of understanding brain metastasis is appropriate model system to understand dynamic interaction of cancer cells and brain cellular players. To meet this challenge, microfluidic-based devices are employed which can mimic the dynamic conditions as well as can be used for culturing human cells for personalized therapy. In this review, we have systematically reviewed the current status of the role of cellular players in brain metastasis along with explaining how translational approach of microfluidics can be employed for finding new drug target as well as biomarker for brain metastasis. Finally, we have also commented on the mechanism of action of drugs against brain metastasis.

Lassman, A. B., & DeAngelis, L. M. (2003). Brain metastases. Neurologic Clinics, 21(1), 1–23.PubMed

Murrell, D., Foster, PJ., and Chambers, Ann F. (2014). Brain metastases from breast cancer: lessons from experimental magnetic resonance imaging studies and clinical implications. Medical Biophysics Publications. Paper 36.

Nayak, L., Lee, E. Q., & Wen, P. Y. (2012). Epidemiology of brain metastases. Current Oncology Reports, 14(1), 48–54.PubMed

Markwell, S. M., & Weed, S. A. (2015). Tumor and stromal-based contributions to head and neck squamous cell carcinoma invasion. Cancers, 7(1), 382–406.PubMedPubMedCentral

Miller, S., Senior, P. V., Prakash, M., Apostolopoulos, V., Sakkal, S., & Nurgali, K. (2016). Leukocyte populations and IL-6 in the tumor microenvironment of an orthotopic colorectal cancer model. Acta Biochimica et Biophysica Sinica, 48(4), 334–341.PubMedPubMedCentral

Place, A. E., Huh, S. J., & Polyak, K. (2011). The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Research, 13(6), 227.PubMed

Hoshide, R., & Jandial, R. (2017). The role of the neural niche in brain metastasis. Clinical & Experimental Metastasis, 1–8.

Madden, K. S., Szpunar, M. J., & Brown, E. B. (2011). β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell lines. Breast Cancer Research and Treatment, 130(3), 747–758.PubMedPubMedCentral

Wong, H. P. S., Yu, L., Lam, E. K. Y., Tai, E. K. K., Wu, W. K. K., & Cho, C.-H. (2007). Nicotine promotes colon tumor growth and angiogenesis through β-adrenergic activation. Toxicological Sciences, 97(2), 279–287.PubMed

10.

DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., Rugo, H. S., Hwang, E. S., Jirström, K., West, B. L., & Coussens, L. M. (2011). Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery, 1(1), 54–67.PubMedPubMedCentral

11.

DeNardo, D. G., & Coussens, L. M. (2007). Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research, 9(4), 212.PubMed

12.

Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454(7203), 436–444.PubMed

13.

Gupta, G. P., Nguyen, D. X., Chiang, A. C., Bos, P. D., Kim, J. Y., Nadal, C., Gomis, R. R., Manova-Todorova, K., & Massagué, J. (2007). Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature, 446(7137), 765–770.PubMed

14.

Reymond, N., d'Água, B. B., & Ridley, A. J. (2013). Crossing the endothelial barrier during metastasis. Nature Reviews Cancer, 13(12), 858–870.PubMed

15.

Chen, Q., Zhang, X. H.-F., & Massagué, J. (2011). Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell, 20(4), 538–549.PubMedPubMedCentral

16.

Bos, P. D., Zhang, X. H.-F., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., Minn, A. J., van de Vijver, M. J., Gerald, W. L., Foekens, J. A., & Massagué, J. (2009). Genes that mediate breast cancer metastasis to the brain. Nature, 459(7249), 1005–1009.PubMedPubMedCentral

17.

Eichler, A. F., Chung, E., Kodack, D. P., Loeffler, J. S., Fukumura, D., & Jain, R. K. (2011). The biology of brain metastases—translation to new therapies. Nature Reviews Clinical Oncology, 8(6), 344–356.PubMedPubMedCentral

18.

Sofroniew, M. V., & Vinters, H. V. (2010). Astrocytes: biology and pathology. Acta Neuropathologica, 119(1), 7–35.PubMed

19.

Valiente, M., Obenauf, A. C., Jin, X., Chen, Q., Zhang, X. H.-F., Lee, D. J., Chaft, J. E., Kris, M. G., Huse, J. T., Brogi, E., & Massagué, J. (2014). Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell, 156(5), 1002–1016.PubMedPubMedCentral

20.

Sofroniew, M. V. (2005). Reactive astrocytes in neural repair and protection. The Neuroscientist, 11(5), 400–407.PubMed

21.

Sofroniew, M. V. (2009). Molecular dissection of reactive astrogliosis and glial scar formation. Trends in Neurosciences, 32(12), 638–647.PubMedPubMedCentral

22.

Chen, Q., Boire, A., Jin, X., Valiente, M., Er, E. E., Lopez-Soto, A., S. Jacob, L., Patwa, R., Shah, H., Xu, K., Cross, J. R., & Massagué, J. (2016). Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature, 533(7604), 493–498.PubMedPubMedCentral

23.

Wang, L., Cossette, S. M., Rarick, K. R., Gershan, J., Dwinell, M. B., Harder, D. R., & Ramchandran, R. (2013). Astrocytes directly influence tumor cell invasion and metastasis in vivo. PLoS One, 8(12), e80933. https://doi.org/10.1371/journal.pone.0080933.CrossRefPubMedPubMedCentral

24.

Malanchi, I., & Huelsken, J. (2009). Cancer stem cells: never Wnt away from the niche. Current Opinion in Oncology, 21(1), 41–46.PubMed

25.

Moore, K. A., & Lemischka, I. R. (2006). Stem cells and their niches. Science, 311(5769), 1880–1885.PubMed

26.

Li, L., & Neaves, W. B. (2006). Normal stem cells and cancer stem cells: the niche matters. Cancer Research, 66(9), 4553–4557.PubMed

27.

Scadden, D. T. (2006). The stem-cell niche as an entity of action. Nature, 441(7097), 1075–1079.PubMed

28.

Gomi, H., Yokoyama, T., & Itohara, S. (2010). Role of GFAP in morphological retention and distribution of reactive astrocytes induced by scrapie encephalopathy in mice. Brain Research, 1312, 156–167.PubMed

29.

Li, L., Lundkvist, A., Andersson, D., Wilhelmsson, U., Nagai, N., Pardo, A. C., Nodin, C., Ståhlberg, A., Aprico, K., Larsson, K., Yabe, T., Moons, L., Fotheringham, A., Davies, I., Carmeliet, P., Schwartz, J. P., Pekna, M., Kubista, M., Blomstrand, F., Maragakis, N., Nilsson, M., & Pekny, M. (2008). Protective role of reactive astrocytes in brain ischemia. Journal of Cerebral Blood Flow & Metabolism, 28(3), 468–481.

30.

Perry, V. H., & Teeling, J. (2013). Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Seminars in Immunopathology, 35(5), 601–612. https://doi.org/10.1007/s00281-013-0382-8.CrossRefPubMedPubMedCentral

31.

Leitinger, N., & Schulman, I. G. (2013). Phenotypic polarization of macrophages in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(6), 1120–1126.PubMedPubMedCentral

32.

Ellert-Miklaszewska, A., Dabrowski, M., Lipko, M., Sliwa, M., Maleszewska, M., & Kaminska, B. (2013). Molecular definition of the pro-tumorigenic phenotype of glioma-activated microglia. Glia, 61(7), 1178–1190.PubMed

33.

Gabrusiewicz, K., Ellert-Miklaszewska, A., Lipko, M., Sielska, M., Frankowska, M., & Kaminska, B. (2011). Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One, 6(8), e23902.PubMedPubMedCentral

34.

Takeda, K., & Akira, S. (2000). STAT family of transcription factors in cytokine-mediated biological responses. Cytokine & Growth Factor Reviews, 11(3), 199–207.

35.

Wei, J., Gabrusiewicz, K., & Heimberger, A. (2013). The controversial role of microglia in malignant gliomas. Clinical and Developmental Immunology, 2013, 285246.PubMedPubMedCentral

36.

Yu, H., Pardoll, D., & Jove, R. (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer, 9(11), 798–809.PubMedPubMedCentral

37.

Juedes, A. E., & Ruddle, N. H. (2001). Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. The Journal of Immunology, 166(8), 5168–5175.PubMed

38.

Ulvestad, E., Williams, K., Bjerkvig, R., Tiekotter, K., Antel, J., & Matre, R. (1994). Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. Journal of Leukocyte Biology, 56(6), 732–740.PubMed

39.

Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000). M-1/M-2 macrophages and the Th1/Th2 paradigm. The Journal of Immunology, 164(12), 6166–6173.PubMed

40.

Pace, J., & Russell, S. (1981). Activation of mouse macrophages for tumor cell killing. I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide. The Journal of Immunology, 126(5), 1863–1867.PubMed

41.

Feng, X., Szulzewsky, F., Yerevanian, A., Chen, Z., Heinzmann, D., Rasmussen, R. D., et al. (2015). Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis. Oncotarget, 6(17), 15077.PubMedPubMedCentral

42.

Mantovani, A., Sozzani, S., Locati, M., Allavena, P., & Sica, A. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology, 23(11), 549–555.PubMed

43.

Brantley, E. C., & Benveniste, E. N. (2008). Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Molecular Cancer Research, 6(5), 675–684.PubMed

44.

Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mulé, J., Kerr, W. G., Jove, R., Pardoll, D., & Yu, H. (2005). Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Medicine, 11(12), 1314–1321.PubMed

45.

Pollard, J. W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer, 4(1), 71–78.PubMed

46.

Komohara, Y., Ohnishi, K., Kuratsu, J., & Takeya, M. (2008). Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. The Journal of Pathology, 216(1), 15–24.PubMed

47.

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386.PubMed

48.

Zhou, W., & Slingerland, J. M. (2014). Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nature Reviews Cancer, 14(1), 26–38.PubMed

49.

Witzel, I., Oliveira-Ferrer, L., Pantel, K., Müller, V., & Wikman, H. (2016). Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Research : BCR, 18, 8. https://doi.org/10.1186/s13058-015-0665-1.CrossRefPubMed

50.

Kaiser, J. (2010). Cancer’s circulation problem. American Association for the Advancement of Science.

51.

Holmes, K., Roberts, O. L., Thomas, A. M., & Cross, M. J. (2007). Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cellular Signalling, 19(10), 2003–2012.PubMed

52.

Chung, A. S., Lee, J., & Ferrara, N. (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. Nature Reviews Cancer, 10(7), 505–514.PubMed

53.

Brusselmans, K., Bono, F., Collen, D., Herbert, J.-M., Carmeliet, P., & Dewerchin, M. (2005). A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. Journal of Biological Chemistry, 280(5), 3493–3499.PubMed

54.

Gerber, H.-P., Malik, A. K., Solar, G. P., Sherman, D., Liang, X. H., Meng, G., Hong, K., Marsters, J. C., & Ferrara, N. (2002). VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature, 417(6892), 954–958.PubMed

55.

He, S., Nakada, D., & Morrison, S. J. (2009). Mechanisms of stem cell self-renewal. Annual Review of Cell and Developmental Biology, 25(1), 377–406. https://doi.org/10.1146/annurev.cellbio.042308.113248.CrossRefPubMed

56.

Sacco, A., Doyonnas, R., Kraft, P., Vitorovic, S., & Blau, H. M. (2008). Self-renewal and expansion of single transplanted muscle stem cells. Nature, 456(7221), 502–506.PubMedPubMedCentral

57.

Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A. B., Shi, Q., McLendon, R. E., Bigner, D. D., & Rich, J. N. (2006). Stem cell–like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Research, 66(16), 7843–7848.PubMed

58.

Zhao, D., Pan, C., Sun, J., Gilbert, C., Drews-Elger, K., Azzam, D., et al. (2015). VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene, 34(24), 3107–3119.PubMed

59.

De Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., & Williams, L. T. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 255(5047), 989–991.PubMed

60.

Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature, 376(6535), 66–70.

61.

Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature, 376(6535), 62–66.PubMed

62.

Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006). VEGF receptor signalling? In control of vascular function. Nature Reviews Molecular Cell Biology, 7(5), 359–371.PubMed

63.

Hamerlik, P., Lathia, J. D., Rasmussen, R., Wu, Q., Bartkova, J., Lee, M., Moudry, P., Bartek Jr., J., Fischer, W., Lukas, J., Rich, J. N., & Bartek, J. (2012). Autocrine VEGF–VEGFR2–neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. Journal of Experimental Medicine, 209(3), 507–520.PubMed

64.

Couzin-Frankel, J., & Ogale, Y. (2011). Once on ‘Fast track,’ avastin now derailed. Science, 333(6039), 143–144. https://doi.org/10.1126/science.333.6039.143.CrossRefPubMed

65.

Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 8, 592. https://doi.org/10.1038/nrc2442.CrossRefPubMedPubMedCentral

66.

Ebos, J. M., Lee, C. R., & Kerbel, R. S. (2009). Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clinical Cancer Research, 15(16), 5020–5025.PubMedPubMedCentral

67.

Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., Rolland, F., Demkow, T., Hutson, T. E., Gore, M., Freeman, S., Schwartz, B., Shan, M., Simantov, R., & Bukowski, R. M. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine, 356(2), 125–134.PubMed

68.

Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., Chen, I., Bycott, P. W., Baum, C. M., & Figlin, R. A. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine, 356(2), 115–124.PubMed

69.

Zivi, A., Cerbone, L., Recine, F., & Sternberg, C. N. (2012). Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Expert Opinion on Drug Safety, 11(5), 851–859. https://doi.org/10.1517/14740338.2012.712108.CrossRefPubMed

70.

Escudier, B., & Gore, M. (2011). Axitinib for the management of metastatic renal cell carcinoma. Drugs in R&D, 11(2), 113–126. https://doi.org/10.2165/11591240-000000000-00000.CrossRef

71.

Ashman, L. K. (1999). The biology of stem cell factor and its receptor C-kit. The International Journal of Biochemistry & Cell Biology, 31(10), 1037–1051.

72.

Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J. H., Ashman, L. K., & Kanayama, Y. (1993). Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. The Journal of Clinical Investigation, 92(4), 1736–1744.PubMedPubMedCentral

73.

Yavuz, A. S., Lipsky, P. E., Yavuz, S., Metcalfe, D. D., & Akin, C. (2002). Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood, 100(2), 661–665.PubMed

74.

Yarden, Y., Kuang, W.-J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T., et al. (1987). Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. The EMBO Journal, 6(11), 3341–3351.PubMedPubMedCentral

75.

Giebel, L., Strunk, K., Holmes, S., & Spritz, R. (1992). Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. Oncogene, 7(11), 2207–2217.PubMed

76.

Caruana, G., Cambareri, A. C., & Ashman, L. K. (1999). Isoforms of c-kit differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene, 18(40), 5573–5581.PubMed

77.

Heldin, C.-H., Östman, A., & Rönnstrand, L. (1998). Signal transduction via platelet-derived growth factor receptors. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1378(1), F79–F113.

78.

Heldin, C.-H., & Westermark, B. (1999). Mechanism of action and in vivo role of platelet-derived growth factor. Physiological Reviews, 79(4), 1283–1316.PubMed

79.

Dibb, N. J., Dilworth, S. M., & Mol, C. D. (2004). Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nature Reviews Cancer, 4(9), 718–727.PubMed

80.

Chen, Z., Xu, X., & Hu, J. (2016). Role of pericytes in angiogenesis: focus on cancer angiogenesis and anti-angiogenic therapy. Neoplasma, 63(2), 173–182.PubMed

81.

Borea, P. A., Gessi, S., Merighi, S., & Varani, K. (2016). Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects? Trends in Pharmacological Sciences, 37(6), 419–434.PubMed

82.

Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013). Immunity, inflammation and cancer: a leading role for adenosine. Nature Reviews Cancer, 13(12), 842–857.PubMed

83.

Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2017). Pathologic overproduction: the bad side of adenosine. British Journal of Pharmacology., 174, 1945–1960.PubMedPubMedCentral

84.

Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2(2), 127–137.PubMed

85.

Herbst, R. S., & Shin, D. M. (2002). Monoclonal antibodies to target epidermal growth factor receptor–positive tumors. Cancer, 94(5), 1593–1611.PubMed

86.

Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Reviews Drug Discovery, 4(12), 988–1004.PubMed

87.

Nishinaka, T., & Yabe-Nishimura, C. (2001). EGF receptor-ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress. Free Radical Biology and Medicine, 31(2), 205–216.PubMed

88.

Kumar, N., Prasad, P., Jash, E., Jayasundar, S., Singh, I., Alam, N., Murmu, N., Somashekhar, S. P., Goldman, A., & Sehrawat, S. (2018). cAMP regulated EPAC1 supports microvascular density, angiogenic and metastatic properties in a model of triple negative breast cancer. Carcinogenesis. https://doi.org/10.1093/carcin/bgy090.

89.

Majumder, B., Baraneedharan, U., Thiyagarajan, S., Radhakrishnan, P., Narasimhan, H., Dhandapani, M., Brijwani, N., Pinto, D. D., Prasath, A., Shanthappa, B. U., Thayakumar, A., Surendran, R., Babu, G. K., Shenoy, A. M., Kuriakose, M. A., Bergthold, G., Horowitz, P., Loda, M., Beroukhim, R., Agarwal, S., Sengupta, S., Sundaram, M., & Majumder, P. K. (2015). Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nature Communications, 6, 6169. https://doi.org/10.1038/ncomms7169.CrossRefPubMedPubMedCentral

90.

Kaiser, J. (2010). Cancer’s circulation problem. Science, 327(5969), 1072–1074. https://doi.org/10.1126/science.327.5969.1072.CrossRefPubMed

91.

Stott, S. L., Hsu, C.-H., Tsukrov, D. I., Yu, M., Miyamoto, D. T., Waltman, B. A., Rothenberg, S. M., Shah, A. M., Smas, M. E., Korir, G. K., Floyd, F. P., Gilman, A. J., Lord, J. B., Winokur, D., Springer, S., Irimia, D., Nagrath, S., Sequist, L. V., Lee, R. J., Isselbacher, K. J., Maheswaran, S., Haber, D. A., & Toner, M. (2010). Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National Academy of Sciences, 107(43), 18392–18397. https://doi.org/10.1073/pnas.1012539107.CrossRef

92.

Dharmasiri, U., Njoroge, S. K., Witek, M. A., Adebiyi, M. G., Kamande, J. W., Hupert, M. L., Barany, F., & Soper, S. A. (2011). High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Analytical Chemistry, 83(6), 2301–2309. https://doi.org/10.1021/ac103172y.CrossRefPubMedPubMedCentral

93.

Hoshino, K., Huang, Y.-Y., Lane, N., Huebschman, M., Uhr, J. W., Frenkel, E. P., & Zhang, X. (2011). Microchip-based immunomagnetic detection of circulating tumor cells. Lab on a Chip, 11(20), 3449–3457. https://doi.org/10.1039/C1LC20270G.CrossRefPubMedPubMedCentral

94.

Kang, J. H., Krause, S., Tobin, H., Mammoto, A., Kanapathipillai, M., & Ingber, D. E. (2012). A combined micromagnetic-microfluidic device for rapid capture and culture of rare circulating tumor cells. Lab on a Chip, 12(12), 2175–2181. https://doi.org/10.1039/C2LC40072C.CrossRefPubMed

95.

Zheng, S., Lin, H. K., Lu, B., Williams, A., Datar, R., Cote, R. J., & Tai, Y. C. (2011). 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomedical Microdevices, 13(1), 203–213. https://doi.org/10.1007/s10544-010-9485-3.CrossRefPubMed

96.

Hou, H. W., Li, Q. S., Lee, G. Y., Kumar, A. P., Ong, C. N., & Lim, C. T. (2009). Deformability study of breast cancer cells using microfluidics. Biomedical Microdevices, 11(3), 557–564. https://doi.org/10.1007/s10544-008-9262-8.CrossRefPubMed

97.

TruongVo, T. N., Kennedy, R. M., Chen, H., Chen, A., Berndt, A., Agarwal, M., Zhu, L., Nakshatri, H., Wallace, J., Na, S., Yokota, H., & Ryu, J. E. (2017). Microfluidic channel for characterizing normal and breast cancer cells. Journal of Micromechanics and Microengineering, 27(3), 035017.

98.

Mak, M., Reinhart-King, C. A., & Erickson, D. (2013). Elucidating mechanical transition effects of invading cancer cells with a subnucleus-scaled microfluidic serial dimensional modulation device. Lab on a Chip, 13(3), 340–348. https://doi.org/10.1039/C2LC41117B.CrossRefPubMedPubMedCentral

99.

Riahi, R., Yang, Y. L., Kim, H., Jiang, L., Wong, P. K., & Zohar, Y. (2014). A microfluidic model for organ-specific extravasation of circulating tumor cells. Biomicrofluidics, 8(2), 024103. https://doi.org/10.1063/1.4868301.CrossRefPubMedPubMedCentral

100.

Sun, B., Hu, S., Sun, D., and Lam, R. H. W. (2017). A microfluidic device for isolation and characterization of transendothelial migrating cancer cells. Biomicrofluidics, 11(1):014105. https://doi.org/10.1063/1.4974012.

101.

Rothbauer, M., Zirath, H., & Ertl, P. (2018). Recent advances in microfluidic technologies for cell-to-cell interaction studies. Lab on a Chip, 18(2), 249–270. https://doi.org/10.1039/c7lc00815e.CrossRefPubMed

102.

Terrell-Hall, T. B., Ammer, A. G., Griffith, J. I. G., & Lockman, P. R. (2017). Permeability across a novel microfluidic blood-tumor barrier model. Fluids and Barriers of the CNS, 14(1), 3. https://doi.org/10.1186/s12987-017-0050-9.CrossRefPubMedPubMedCentral

103.

Higashimori, H., & Yang, Y. (2012). Imaging analysis of neuron to glia interaction in microfluidic culture platform (MCP)-based neuronal axon and glia co-culture system. Journal of Visualized Experiments: JoVE, 68, 4448. https://doi.org/10.3791/4448.CrossRef

104.

Pandya, H. J., Dhingra, K., Prabhakar, D., Chandrasekar, V., Natarajan, S. K., Vasan, A. S., Kulkarni, A., & Shafiee, H. (2017). A microfluidic platform for drug screening in a 3D cancer microenvironment. Biosensors & Bioelectronics, 94, 632–642. https://doi.org/10.1016/j.bios.2017.03.054.CrossRef

Titel: Perspectives on the role of brain cellular players in cancer-associated brain metastasis: translational approach to understand molecular mechanism of tumor progression
verfasst von: Masoom Raza
Peeyush Prasad
Pragya Gupta
Naveen Kumar
Taruna Sharma
Mandeep Rana
Aaron Goldman
Seema Sehrawat
Publikationsdatum: 04.10.2018
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 4/2018
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-018-9766-5

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Perspectives on the role of brain cellular players in cancer-associated brain metastasis: translational approach to understand molecular mechanism of tumor progression

Abstract

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment

MACC1—the first decade of a key metastasis molecule from gene discovery to clinical translation

Cross-talk between lung cancer and bones results in neutrophils that promote tumor progression

Applications of Raman spectroscopy in cancer diagnosis

WNT5A as a therapeutic target in breast cancer

Metabolic reprogramming of mitochondrial respiration in metastatic cancer

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie